99007123 - OUTPACE

Information

• Trademark
• 99007123

• Source

• Serial Number

  99007123

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations

• Filing Date

  January 17, 2025
  a year ago

• Transaction Date

  July 17, 2025
  a year ago

• Status Date

  July 07, 2025
  a year ago

• Location Date

  July 07, 2025
  a year ago

• Status Code

  641

• Current Location

  TMO LAW OFFICE 303

  Employee Name

  THINGVOLD,CALDER J

• Attorney Docket Number

  T-4830/1 US

  Attorney Name

  Sydney R. Jensen

  Law Office Assigned Location Code

  T40

• Owners

  • Outpace Bio, Inc.

Case File Statements

• GS0051: Medicines; drugs; pharmaceuticals; pharmaceutical preparations; therapeutics; therapeutic pharmaceuticals; therapeutic agents; cell therapies; biopharmaceuticals; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; drugs for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cells for medical or clinical purposes; viral or non-viral delivery vectors for medical or clinical purposes; proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; targeted cell therapies; cell therapy products; gene therapy products; therapeutic antigens and antibodies; engineered cells; bioengineered cells; cell engineering platforms; protein design platforms; computational protein design platforms; AI-powered protein design platforms; pharmaceutical preparations developed with a computational protein design platform; pharmaceutical preparations developed with AI-powered protein design platforms; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;

Case File Event Statements

• 1/17/2025 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 6/27/2025 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 1/17/2025 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/7/2025 - a year ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 7/7/2025 - a year ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 7/7/2025 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT